Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Conditions

• Lung Cancer Metastatic
• Renal Cell Carcinoma
• Head and Neck Cancer
• Triple Negative Breast Cancer
• Merkel Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Urothelial Carcinoma
• Colorectal Carcinoma With Microsatellite Instability
• Esophageal Squamous Cell Carcinoma
• Endometrial Carcinoma
• Cervical Cancer
• Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma
• Basal Cell Carcinoma
• Squamous Skin Carcinoma

Interventions

• DRUG: Reduced dose intensity of IO

Sponsor

UNICANCER